Medication info
Janumics Tablets 50/1000 mg

Janumics Tablets 50/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Phosphate›62.04mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Dasan Pharmaceutical Co., Ltd.
Appearance
Red oval film-coated tablets
Packaging
30 tablets (10 tablets/PTP x 3) - 30 tablets/PTP
Approval status
Active

MFDS item code 201503177 · Approved 2015.05.27 · Insurance code 678600490

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this drug should be determined based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this drug should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this drug is one 50/500 mg tablet twice daily; the dose may be increased to one 50/1000 mg tablet twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, section 2. Patients in whom this drug is contraindicated). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching to this drug from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, section 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this drug. Any change in the treatment regimen for type 2 diabetes may alter glycemic control, so caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, section 2. Patients in whom this drug is contraindicated).

Ingredients

Manufacturer
Dasan Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication helps improve blood sugar control in patients with type 2 diabetes who have difficulty managing their blood sugar levels through dietary and exercise regimens by using sitagliptin and metformin together.

How to take

Adult dose

For antidiabetic therapy, the dose of this drug should be determined based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this drug should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this drug is one 50/500 mg tablet twice daily; the dose may be increased to one 50/1000 mg tablet twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, section 2. Patients in whom this drug is contraindicated). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching to this drug from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, section 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this drug. Any change in the treatment regimen for type 2 diabetes may alter glycemic control, so caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, section 2. Patients in whom this drug is contraindicated).

Precautions

This medication is used for the treatment of diabetes and contains two components: sitagliptin and metformin. First, serious allergic reactions may occur while taking this medication, so if symptoms like skin rash or difficulty breathing appear, discontinue immediately and consult a physician. This medication may cause pancreatitis, which is inflammation of the pancreas; therefore, if you experience abdominal pain, vomiting, or severe abdominal pain, you should inform healthcare professionals immediately. Additionally, the metformin component can rarely lead to a serious metabolic disorder called lactic acidosis; thus, if symptoms such as sudden muscle pain, difficulty breathing, or lethargy arise, discontinue this medication immediately and seek medical attention. Patients with poor kidney function or specific conditions such as severe infections, dehydration, or heart failure may be at risk when taking this medication, so they must consult a physician before use. When undergoing surgery or tests that use iodine contrast, this medication must be temporarily stopped, and should be resumed only after kidney function has returned to normal. It is advised that pregnant or potentially pregnant women and nursing mothers avoid taking this medication. During the use of this medication, symptoms of hypoglycemia may occur, so regular meals should be maintained and sudden exercise or skipping meals should be avoided. Furthermore, the risk of hypoglycemia may increase when taken with other hypoglycemic agents, so dosage adjustments should be made according to a physician's instructions. This medication may cause gastrointestinal disturbances (diarrhea, nausea, vomiting, etc.), and if symptoms are severe, healthcare professionals should be consulted. Regular blood tests and kidney function tests should be performed, especially for the elderly or patients with diminished kidney function, as they require extra caution. It is best to avoid alcohol consumption while taking this medication as excessive drinking can increase the risk of lactic acidosis. Rarely, severe joint pain or skin disorders can occur, so if such symptoms arise, inform a physician immediately and discontinue medication. Finally, if any unusual symptoms occur while taking this medication, it is important to consult healthcare professionals promptly for appropriate measures.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 24 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • cutaneous vasculitis
  • rash
  • urticaria
  • severe and debilitating arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • vitamin B12 deficiency
  • dyspnea
  • unstable angina
  • dizziness
  • acute renal failure
  • decreased appetite
  • itching
  • weight loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container that is air-tight and kept at room temperature between 1 degrees to 30 degrees Celsius. Proper storage will help maintain the effectiveness of the medication over time.

Appearance and packaging

Appearance

Red oval film-coated tablets

Package unit

30 tablets (10 tablets/PTP x 3) - 30 tablets/PTP

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.